Washington, District of Columbia, United States, April 2026 — Christie Bloomquist has joined Boehringer Ingelheim as Senior Vice President, Corporate Affairs, U.S. Human Pharma, and President of the Boehringer Cares Foundation. In this dual leadership role, she will lead corporate affairs strategy, government engagement, and policy advocacy, while also advancing the organization’s philanthropic initiatives and community impact agenda.
Christie Bloomquist brings extensive experience in corporate affairs, public policy, and healthcare advocacy across leading global pharmaceutical organizations. Prior to joining Boehringer Ingelheim, she served as Vice President, U.S. Strategy and Government Affairs at Astellas Pharma, where she played a key role in shaping strategic policy direction and strengthening stakeholder engagement.
Before Astellas, she spent over nine years at AstraZeneca, holding senior leadership roles including Vice President, U.S. Corporate Affairs and Government Affairs and Head of Federal Government Affairs & Policy. During this tenure, she led high-impact advocacy initiatives, policy strategy, and government engagement across the U.S. healthcare ecosystem.
Earlier in her career, Christie Bloomquist served as a Partner at Hogan Lovells and Reed Smith LLP, advising clients in the life sciences and healthcare sectors on regulatory, policy, and legal matters. She began her professional journey in leading law firms, building deep expertise in healthcare law and policy.
She holds a Doctor of Law (JD) and a Master of Health Administration (MHA) from Washington University in St. Louis, reflecting a strong foundation in both legal and healthcare systems.
Boehringer Ingelheim is a leading global pharmaceutical company focused on improving human and animal health through innovative therapies. With a strong commitment to research and development, the company addresses unmet medical needs across therapeutic areas including respiratory, cardiovascular, oncology, and metabolic diseases.
Guided by a patient-centric approach and a deep commitment to sustainability, Boehringer Ingelheim continues to drive innovation while delivering meaningful impact for patients, communities, and healthcare systems worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
